Associated Press | Federal health experts say a first-of-a-kind
multiple sclerosis drug from Novartis is effective at controlling
tremors, concentration problems and other symptoms of the debilitating
Swiss drugmaker Novartis has asked the Food and Drug Administration to
approve its drug Gilenia as the first pill for multiple sclerosis. All
existing drugs require frequent injections or infusions.
The Food and Drug Administration’s panel of nervous system experts voted 25-0 that Gilenia helps reduce relapses of multiple sclerosis, which causes of host of movement and cognitive problems.
The panel is scheduled to vote on the drug’s safety Thursday afternoon. The FDA is not required to follow the group’s advice, though it usually does.